CurrentBlue Cross Blue Shield - Rhode IslandPolicy N/A

Intra‑Articular Hyaluronan Injections for Osteoarthritis

This policy governs coverage for intra-articular hyaluronan (viscosupplementation) injections for osteoarthritis for Commercial Products of Blue Cross & Blue Shield of Rhode Island; Medicare Advantage follows CMS NCD/LCD.

Policy Summary

PayerBlue Cross Blue Shield - Rhode Island

PolicyIntra‑Articular Hyaluronan Injections for Osteoarthritis

Policy CodePolicy N/A

Change TypeNo material change

Effective DateJan 2, 2016

Next Review DateN/A

Key ActionDo not submit claims for intra‑articular hyaluronan injections for Commercial Products as they are considered not medically necessary.

SourceLink

POLICY UPDATE CHANGES

No material clinical or coverage changes in this revision.

Not medically necessarycoverage stance for IAHA

MultipleHCPCS J-codes not covered

20610/20611CPT codes referenced

07/02/2025last updated

AAOS/ACR/OARSI/NICEmajor guidelines cited

Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.

Coverage Determination

Not Medically Necessary - Commercial Products

Commercial Products coverage determination

Commercial coverage stance: Intra-articular hyaluronan injections of the knee and all other joints are considered not medically necessary as the evidence is insufficient to determine the effects of the technology on health outcomes.

Applies to Commercial Products only; Medicare Advantage follows CMS NCD/LCD.

This policy applies to Commercial Products only. For Medicare Advantage plans, Blue Cross & Blue Shield of Rhode Island follows Centers for Medicare & Medicaid Services (CMS) National and Local Coverage Determinations (NCD/LCD); refer to those CMS determinations for coverage guidance for Medicare Advantage members. Commercial Products determinations in this policy do not alter CMS-directed coverage for Medicare Advantage beneficiaries.

Services that are determined to be not medically necessary or that are non-covered benefits are excluded from payment under this policy. Providers may not charge the member for services that are denied as not medically necessary unless the member has been informed in advance and has provided written agreement to self-pay. Benefits and eligibility are governed by the member’s subscriber agreement, certificate, or employer agreement.

For Commercial Products, intra-articular hyaluronan (IAHA) injections for the knee and for all other joints are considered not medically necessary. The policy explicitly lists the following HCPCS (J) codes as not medically necessary: J7318, J7320, J7321, J7322, J7323, J7324, J7325, J7326, J7327, J7328, J7329, J7331, J7332. In addition, CPT 20610 (arthrocentesis, aspiration and/or injection, major joint or bursa) is considered not medically necessary when billed with one of the listed J-codes.

Claims for services determined to be not medically necessary under this policy are subject to denial and are not payable by the plan. Providers should verify member benefits and eligibility prior to providing services; if a service is denied as not medically necessary, the provider may not bill the member unless the member was informed and provided written consent to self-pay in advance.

Billing and Codes

Not Medically Necessary HCPCS (J) CodesHCPCSNot Covered

J7318	Hyaluronan or derivative, durolane, for intra-articular injection, 1 mg.
J7320	Hyaluronan or derivative, GenVisc 850, for intra-articular injection, 1 mg.
J7321	Hyaluronan or derivative, Hyalgan or Supartz, for intra-articular injection, per dose.
J7322	Hyaluronan or derivative, hymovis or hymovis one, for intraarticular injection, 1 mg.
J7323	Hyaluronan or derivative, Euflexxa, for intra-articular injection, per dose.
J7324	Hyaluronan or derivative, Orthovisc, for intra-articular injection, per dose.
J7325	Hyaluronan or derivative, Synvisc or Synvisc-One, for intra-articular injection, 1 mg.
J7326	Hyaluronan or derivative, Gel-One, for intra-articular injection, per dose.
J7327	Hyaluronan or derivative, Monovisc, for intra-articular injection, per dose.
J7328	Hyaluronan or derivative, Gel-syn, for intra-articular injection, 0.1 mg.

1–10 of 13

1/2

Not Medically Necessary CPT Codes when billed with listed J-codesCPTNot Covered

20610

Arthrocentesis, aspiration and/or injection, major joint or bursa (e.g., shoulder, hip, knee joint, subacromial bursa)

CPT codes mentionedCPT

20611

Arthrocentesis, aspiration and/or injection, major joint or bursa (e.g., shoulder, hip, knee, subacromial bursa); with ultrasound guidance, with permanent recording and reporting

Provider Requirements & Billing Guidance

Prior Authorization

Prior authorization: Not applicable. Providers do not need to obtain prior authorization for intra-articular hyaluronan injections under this policy.

Note

Benefit Verification

Benefits may vary between groups and contracts. Providers must verify member-specific benefits and eligibility before rendering services. Refer to the member's Benefit Booklet, Evidence of Coverage, or Subscriber Agreement for coverage details.

Contact the provider call center for member-specific benefits and eligibility verification.

Documentation Required

Medical Criteria

Medical criteria: Not applicable.

Clinical Background

Knee osteoarthritis (OA) is a common, disabling condition for which there is no curative therapy; management focuses on reducing pain, improving function, and delaying joint replacement. Intra-articular hyaluronan (viscosupplementation) is intended to replace endogenous hyaluronan and restore the viscoelastic properties of synovial fluid, with the goal of improving pain and function. However, the evidence base from randomized trials and systematic reviews is mixed and overall considered insufficient to demonstrate a clinically meaningful benefit for IAHA across joint sites; accordingly, IAHA injections of the knee and other joints are considered not medically necessary for Commercial Products.

Key Definitions

Hyaluronan (hylan, viscosupplementation) — definition and formulation notes

DefinitionHyaluronan is a naturally occurring macromolecule and major component of synovial fluid that contributes to its viscoelastic properties.

Cross-linked forms (hylans)Chemical crosslinking increases molecular weight; cross-linked hyaluronans are referred to as hylans.

Intended roleUsed as an intra-articular injectable to replace endogenous hyaluronan and restore synovial fluid viscoelasticity in osteoarthritic joints.

Common targetMost studies and the FDA-approved indication focus on knee osteoarthritis, though other joints (eg, hip, shoulder) have been investigated.

Pathophysiology noteIn osteoarthritis, hyaluronan chain length and synovial fluid hyaluronan concentration are decreased, which viscosupplementation aims to address.

Policy Revision History & References

2016-02-01effective_date

Policy effective date established.

2025-07-02policy_updatedLatest

Policy last updated (document displays policy last updated date).

2025-03-11reference_accessed

Several bibliographic references (AAOS, NICE, and others) cited with access dates in March 2025 supporting guideline evidence base.